[email protected]   +1 (304) 306-0723

Progressive Supranuclear Palsy (PSP) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030

$6,500.00$19,500.00

Progressive supranuclear palsy (PSP) treatment landscape reflects a huge unmet need, as it is quite dry and limited to symptomatic and supportive care, with no disease-modifying therapies. Emerging therapies like RT-001 (Retrotope), Fasudil (Woolsey), Ezeprogind (AlzProtect), Emeramide (EmeraMed) and Droxidopa (H. Lundbeck) has the potential to overcome the challenges associated with the current therapeutic options in future. Sales of these emerging therapies to treat Progressive Supranuclear Palsy (PSP) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.3 billion market by 2030.

Clear

Description

Progressive supranuclear palsy (PSP) is an adult onset, progressive, sporadic neurodegenerative disease, and an important cause of atypical Parkinsonism. MDS-PSP clinical criteria is the most widely used to define Progressive Supranuclear Palsy (PSP). PSP carries an unfavorable prognosis, with average onset of symptoms in between age 62-66 and is often misdiagnosed as Parkinson disease, Alzheimer disease, corticobasal degeneration and other neurodegenerative disorders making it challenging to diagnose.

The hallmark sign of PSP is progressive ophthalmoplegia – weakness or paralysis of the muscles required for eye movement. PSP shares many of the clinical manifestations of Parkinson’s disease – however, differs in how quickly patients progress with PSP patients progressing much faster. Patients typically become severely disabled and dependent on care within 3-4 years following the onset of initial symptoms. The mean age of PSP is 65 years and is notably higher than idiopathic Parkinson’s disease. Notably, there are no validated risk factors (genetic or environmental) for PSP other than age. However, a genome wide association study showed that variants of the MAPT gene increases the risk of PSP.

Progressive Supranuclear Palsy – Prevalence (Epidemiology)

The criteria most widely used to define Progressive Supranuclear Palsy (PSP) are those of MDS-PSP clinical criteria which was based on the NINDS-SPSP criteria. The NINDS-SPSP criteria, as validated by autopsy, have excellent specificity, around 95% to 100% for probable PSP and around 80% to 93% for possible PSP. The combination of early onset postural instability and falls with vertical ocular motor dysfunction is now usually referred to as Richardson’s syndrome (PSP-RS) and is well captured by the NINDS-SPSP criteria. However, the criteria’s sensitivity for PSP overall is limited (median, 24%; range, 14%–83%) at the first clinical visit.

Progressive supranuclear palsy (PSP) tends to affect 5-17 in 100,000 people. At least 20,000 people in the United States are affected by PSP everywhere. PSP tends to affect men and women equally with this disorder. According to Mellalta Meets analysis, the United States will account for the highest PSP cases in the forecast period from 2021 to 2030. We estimate prevalence of ~47,500 cases of Progressive Supranuclear Palsy (PSP) in the seven major markets, based on the PSP population based epidemiological studies

Progressive Supranuclear Palsy Cases by Clinical Symptoms

Progressive Supranuclear Palsy – Current Market Size & Forecast Trends

The Progressive Supranuclear Palsy market is expected to see high growth during our forecast period. The market in the G7 countries is expected to reach $ 1,349 million by 2030 with a CAGR of 36.5%. The main growth drivers of the PSP market are the increase in prevalence, robust pipeline, the increase in the number of clinical trials, emerging diagnostic tools and government initiatives to create awareness for this disease. The core problem with treatment of PSP and other neurodegenerative disorders, is that by the time these disorders are detected, the brain damage has already occurred.

Treatments that reduce ongoing damage, cannot be expected to reverse damage. So far, we do not have methods to regrow dead neurons, or “vacuum” out toxic protein from neural cells. Still, perhaps these drugs might slow down the rate of progression of PSP, which is commonly fatal over 5-10 years. Stopping or slowing progression is presently the main goal of treatment.

Emerging therapies such as RT-001 (Retrotope), Fasudil (Woolsey), Ezeprogind (AlzProtect), Emeramide (EmeraMed) and Droxidopa (H. Lundbeck), are expected to bring a positive shift to the global market in the coming years due to the launch expected of these therapies.

Progressive Supranuclear Palsy G7 Market Size by Therapies

Report Highlights

  • Progressive Supranuclear Palsy -Current Market Trends
  • Progressive Supranuclear Palsy -Current & Forecasted Cases across the G7 Countries
  • Progressive Supranuclear Palsy -Market Opportunities and Sales Potential for Agents
  • Progressive Supranuclear Palsy -Patient-based Market Forecast to 2030
  • Progressive Supranuclear Palsy -Untapped Business Opportunities
  • Progressive Supranuclear Palsy -Product Positioning Vis-a-vis Competitors’ Products
  • Progressive Supranuclear Palsy -KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

Table of Contents

  • Executive Summary
    • Key Findings
  • Progressive Supranuclear Palsy (PSP) Disease Background
    • Progressive Supranuclear Palsy (PSP) Definition
    • Causes & Symptoms
    • Pathology
    • Diagnosis
    • Differential Diagnosis
  • Epidemiology and Patient Populations
    • Key Findings
    • Methods and data Sources
      • Country Specific Prevalent Populations (US, Germany, France, Italy, Spain, UK, and Japan)
      • Country Specific Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP) Cases
      • Country Specific Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
    • Number of Diagnosed and Drug-Treated Cases of Progressive Supranuclear Palsy (PSP) in the Major Pharmaceutical Markets, 2017-2030
    • Key Sources for Progressive Supranuclear Palsy (PSP) Epidemiology and Model Parameters
      • United States
        • United States Prevalent Populations of Progressive Supranuclear Palsy (PSP)
        • United States Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP)
        • United States Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
      • Germany
        • Germany Prevalent Populations of Progressive Supranuclear Palsy (PSP)
        • Germany Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP)
        • Germany Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
      • France
        • France Prevalent Populations of Progressive Supranuclear Palsy (PSP)
        • France Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP)
        • France Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
      • Italy
        • Italy Prevalent Populations of Progressive Supranuclear Palsy (PSP)
        • Italy Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP)
        • Italy Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
      • Spain
        • Spain Prevalent Populations of Progressive Supranuclear Palsy (PSP)
        • Spain Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP)
        • Spain Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
      • United Kingdom
        • United Kingdom Prevalent Populations of Progressive Supranuclear Palsy (PSP)
        • United Kingdom Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP)
        • United Kingdom Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
      • Japan
        • Japan Prevalent Populations of Progressive Supranuclear Palsy (PSP)
        • Japan Clinical Symptoms Associated Cases of Progressive Supranuclear Palsy (PSP)
        • Japan Diagnosed and Treated Cases of Progressive Supranuclear Palsy (PSP)
  • Current Therapies and Medical Practice
    • Treatments & Medical Practices
    • Treatment patterns in progressive supranuclear palsy
  • Unmet Needs
  • Emerging Therapies
    • Pipeline Overview
    • Therapeutic Developments Pipeline for Progressive Supranuclear Palsy (PSP)
      • Product Analysis
        • Ioflupane 123I (GE Healthcare)
          • Product Profile
          • Clinical Development
        • RT-001 (Retrotope, Inc.)
          • Product Profile
          • Clinical Development
        • AMRS001 (Amarantus Bioscience)) Fasudil (Woolsey Pharmaceuticals)
          • Product Profile
          • Clinical Development
    • Emerging Therapies
      • Therapeutic Developments Pipeline for Progressive Supranuclear Palsy (PSP)
      • Ezeprogind (AlzProtect)
        • Product Profile
        • Clinical Development
      • Emeramide (EmeraMed)
        • Product Profile
        • Clinical Development
      • Droxidopa (H. Lundbeck A/S)
        • Product Profile
        • Clinical Development
      • Bepranemab (UCB)
      • Product Profile
        • Clinical Development
      • NIO-752 (Novartis)
        • Product Profile
        • Clinical Development
      • Tolfenamic Acid (NeuroTau, Inc.)
        • Product Profile
        • Clinical Development
      • ASN-120290 (Asceneuron)
        • Product Profile
        • Clinical Development
      • anti-tau antibody (Aprinoia Therapeutics)
        • Product Profile
        • Clinical Development
      • PRX-005 (Prothena)
        • Product Profile
      • VY-TAU01 (Voyager Therapeutics)
        • Product Profile
  • Future Treatment Paradigm
      • Progressive Supranuclear Palsy (PSP) Competitor Landscape and Approvals Anticipated
      • Future Treatment Algorithms and Competitor Positioning
      • Key Data Summary for Emerging Treatment
  • Economic Cost of Progressive Supranuclear Palsy (PSP)
  • Annual Cost of Current & Emerging Therapies
  • Market Outlook
      • Key Findings
      • Country Specific Market Forecast to 2030
        • Sales of Drugs to Treat Progressive Supranuclear Palsy (PSP) in the Major Pharmaceutical Markets, 2017-2030
        • Patient Share of Progressive Supranuclear Palsy (PSP) Therapies and by Drug
  • Market Forecast by Country
  • United States
    • United States Market for Progressive Supranuclear Palsy (PSP) 2020-2030 (USD Million)
    • United States Market for Progressive Supranuclear Palsy (PSP) by Therapies 2020-2030 (USD Million)
  • Germany
    • Germany Market for Progressive Supranuclear Palsy (PSP) 2020-2030 (USD Million)
    • Germany Market for Progressive Supranuclear Palsy (PSP) by Therapies 2020-2030 (USD Million)
  • France
    • France Market for Progressive Supranuclear Palsy (PSP) 2020-2030 (USD Million)
    • France Market for Progressive Supranuclear Palsy (PSP) by Therapies 2020-2030 (USD Million)
  • Italy
    • Italy Market for Progressive Supranuclear Palsy (PSP) 2020-2030 (USD Million)
    • Italy Market for Progressive Supranuclear Palsy (PSP) by Therapies 2020-2030 (USD Million)
  • Spain
    • Spain Market for Progressive Supranuclear Palsy (PSP) 2020-2030 (USD Million)
    • Spain Market for Progressive Supranuclear Palsy (PSP) by Therapies 2020-2030 (USD Million)
  • United Kingdom
    • United Kingdom Market for Progressive Supranuclear Palsy (PSP) 2020-2030 (USD Million)
    • United Kingdom Market for Progressive Supranuclear Palsy (PSP) by Therapies 2020-2030 (USD Million)
  • Japan
    • Japan Market for Progressive Supranuclear Palsy (PSP) 2020-2030 (USD Million)
    • Japan Market for Progressive Supranuclear Palsy (PSP) by Therapies 2020-2030 (USD Million)
  • Market Drivers and Constraints
    • What Factors Are Driving the Market for Progressive Supranuclear Palsy (PSP)?
    • What Factors Are Constraining the Market for Progressive Supranuclear Palsy (PSP)?
  • Appendix
    • Report Methodology
Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going